None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Normal healthy human volunteers should be included. 2) Subjects between the age above 18 to 65 years from both sex. 3) Patients willing to sign an informed written consent and comply with visit schedules. 4) Patients must be able to communicate effectively with study personnel. 5) Subjects should not have unbroken skin on either hands or feet.
Exclusion criteria
Exclusion criteria: 1) Patient with sign and symptoms of viral, bacterial or auto-immune skin infection. 2) Known positive status and known history for viral, bacterial or auto immune skin infections. 3) Broken,cracked or burnt skin on hands or feets. 4) Volunteers should not have any disease. Especially dermatological diseases should not be included. 5) Subjects on any other experimental treatment within 07 days of the first day of study drug or who have not recovered from the side effects of any such therapy. 6) Patient have history of hospitalized treatment before 07 days. 7) Patient taking any other then investigational drug in last 07 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate and compare the antimicrobial effectiveness of a Octenidine Dihydrochloride 0.3% Hand & Body Wash Gel Vs. propanol-2-ol (60%) and diluted dettol anti-septic solution (1:20) disinfectant solution when used for hygienic handwash purpose.Timepoint: Complete medical examination will be done by principal investigator on screening day along with blood test. Following parameters will be measured on initial(enrollment) day, 07 day and 14 day after screening of skin of hand and feet at each visit: CFU count of culture of micro-organisms before and after application of intervention/comparator agent Examination of hand and feet includes: General Appearance and skin condition of hand and feet | — |
Secondary
| Measure | Time frame |
|---|---|
| To observe any side effect and any serious adverse reactionTimepoint: Any adverse reaction or side effects shall be reported to principal investigator and sponsor immediately. During the Study follow-up visits and after one week of completion of 14 days study, subjects will be consulted for any adverse reaction or side effects is being observed. | — |
Countries
India
Contacts
Accuprec Research Labs Pvt. Ltd.